A federal judge has ruled that CVS' purchase of Aetna was legal under antitrust law; the Trump administration announced $1.8 billion in grants to help states and communities combat the opioid epidemic; Johns Hopkins Medicine has launched the first psychedelic research center in the United States.
A federal judge has approved CVS’ purchase of Aetna, agreeing with a Justice Department decision that the merger is legal under antitrust law, Reuters has reported. A government plan announced in October said it would allow the merger on the condition that the health insurer sell its Medicare prescription drug plan business to WellCare Health Plans. Both deals have already closed, and since then, Centene has agreed to acquire WellCare for $15.27 billion. CVS said the judge’s decision reinforced that CVS and Aetna have already merged.
The Trump administration on Wednesday announced that it is awarding $1.8 billion in grants to help combat the opioid epidemic. Approximately $980 million will go to states and some territories to focus on prevention and treatment, including through expanding rural telemedicine, expanding access to overdose reversal drug naloxone, and prevention programs. According to The Wall Street Journal, another $900 million will go to CDC over 3 years in order to help states and communities track overdose data and implement treatment strategies.
Johns Hopkins Medicine has launched the Center for Psychedelic and Consciousness Research, the first of its kind in the country. The center will study substances like LSD and psilocybin for a variety of mental health conditions, including anorexia, addiction, and depression, reported The New York Times. The center was created with $17 million in funding from private donors and a foundation. Some scientists have been exploring the potential of psychedelics and other recreational drugs for psychiatric problems since the early 2000s.
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen
Report Reveals Mounting Burdens of Drug Shortages on US Health System
June 27th 2025Vizient's 2024 survey reveals a sharp rise in drug shortages across US health care, with pediatric care hit especially hard and labor costs soaring—but the true impact may go far beyond limited medication access, threatening to disrupt the very foundations of how health systems operate.
Read More